Tests a vision measure in people with macular degeneration, Stargardt disease and normal sight
Compares a shape discrimination test with standard vision testing in people with vision loss.
Plain-language title generated from the registry record
Registry title: A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Key facts
- Where
- Dallas, United StatesSee the site
Where in United States
- Retina of North TexasDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanoscope Therapeutics Inc.
- Trial code
- NCT06805474
- Record updated
- 24 March 2025
- Original description
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.Read full original descriptionShow less
A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.
Inclusion: Males and females, age ≥ 18 years; Able to comprehend and give informed consent; Able to comply with testing and all protocol tests; Eligible for 1 of 3 cohorts listed below:; Cohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20/16 to <20/40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20/40 to <20/200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD/GA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20/200 to 20/800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD/GA; Clinical diagnosis of STGD for cohorts 2 and 3; Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3; Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.
Exclusion: Concurrent participation in any interventional clinical trial or receipt of an investigational drug within the previous 6 months; Presence of any condition other than STGD or GA from AMD on slit lamp exam or dilated ophthalmoscopy that impairs visual acuity or visual fields e.g., corneal opacity, visually significant cataract or visual field loss in glaucoma; No intra-vitreal injection with anti-VEGF two weeks prior to the study; Presence of neurological condition that impairs visual acuity; Individuals who refuse or are incapable of performing the MLSDT of BCVA tests; Individuals with retinal prosthesis (such as ARGUS-II).